79 filings
Page 2 of 4
8-K
bj9v3ru 96g55863
27 Sep 22
Other Events
5:00pm
8-K
zop9y
12 Aug 22
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:32am
8-K
toiuefjeaay29t0brf9
8 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:14pm
8-K
8b8k 9qrcy
5 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
gh5nghh oaa37
20 May 22
Submission of Matters to a Vote of Security Holders
4:29pm
8-K
tzgbsb7j15n
16 May 22
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
12:00am
8-K
npxmn3q i1e2vyqc
4 Apr 22
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
4:35pm
8-K
t4qj2 vq7
24 Mar 22
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
4:12pm
8-K
uud21lc
21 Dec 21
PhaseBio Provides Pemziviptadil (PB1046) Program Update
8:03am
8-K
yzlxhh1vxamlzjgp
15 Nov 21
Regulation FD Disclosure
11:32am
8-K
b89tpymrxn
10 Nov 21
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
4:35pm
8-K
33h yq1zd
3 Nov 21
PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab
8:04am
8-K
tgx689aeqqw
15 Sep 21
PhaseBio Appoints William D. Humphries to Board of Directors
8:04am
8-K
wk6v xnygehd1
12 Aug 21
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
10:11am
8-K
qi7c6ul
10 Aug 21
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
8:03am
8-K
c1x xpfq0qgfedk3
17 Jun 21
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
8:13am
8-K
5u9go1z jp
4 Jun 21
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
n2pb5 p1fnc
13 May 21
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
4:06pm
8-K
bec0vspp
19 Mar 21
PhaseBio Announces Pricing of Public Offering of Common Stock
4:08pm
8-K
mwu18t7s12rv0rmr
15 Mar 21
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
8:10am